Ocuphire Pharma ROA 2010-2024 | IRD
Current and historical return on assets (ROA) values for Ocuphire Pharma (IRD) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Ocuphire Pharma ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2024-06-30 |
$-0.01B |
$0.05B |
-27.32% |
| 2024-03-31 |
$-0.01B |
$0.05B |
-21.67% |
| 2023-12-31 |
$-0.01B |
$0.05B |
-20.41% |
| 2023-09-30 |
$0.03B |
$0.05B |
60.73% |
| 2023-06-30 |
$0.02B |
$0.04B |
47.37% |
| 2023-03-31 |
$0.02B |
$0.05B |
56.69% |
| 2022-12-31 |
$0.02B |
$0.05B |
66.67% |
| 2022-09-30 |
$-0.02B |
$0.02B |
-116.46% |
| 2022-06-30 |
$-0.02B |
$0.02B |
-101.15% |
| 2022-03-31 |
$-0.02B |
$0.02B |
-102.13% |
| 2021-12-31 |
$-0.06B |
$0.03B |
-260.47% |
| 2021-09-30 |
$-0.07B |
$0.02B |
-353.85% |
| 2021-06-30 |
$-0.07B |
$0.03B |
-412.50% |
| 2021-03-31 |
$-0.06B |
$0.01B |
-497.96% |
| 2020-12-31 |
$-0.03B |
$0.02B |
-204.08% |
| 2020-09-30 |
$-0.01B |
$0.01B |
-60.61% |
| 2020-06-30 |
$-0.01B |
$0.01B |
-61.54% |
| 2020-03-31 |
$-0.01B |
$0.01B |
-51.06% |
| 2019-12-31 |
$-0.01B |
$0.00B |
-37.04% |
| 2019-09-30 |
$-0.01B |
$0.02B |
-52.94% |
| 2019-06-30 |
$-0.01B |
$0.02B |
-71.64% |
| 2019-03-31 |
$-0.01B |
$0.02B |
-83.58% |
| 2018-12-31 |
$-0.01B |
$0.02B |
-78.87% |
| 2018-09-30 |
$-0.02B |
$0.01B |
-72.29% |
| 2018-06-30 |
$-0.01B |
$0.02B |
-46.81% |
| 2018-03-31 |
$-0.01B |
$0.02B |
-23.08% |
| 2017-12-31 |
$-0.03B |
$0.03B |
-102.97% |
| 2017-09-30 |
$-0.02B |
$0.03B |
-97.87% |
| 2017-06-30 |
$-0.03B |
$0.03B |
-108.70% |
| 2017-03-31 |
$-0.03B |
$0.02B |
-131.76% |
| 2016-12-31 |
$-0.01B |
$0.02B |
-43.96% |
| 2016-09-30 |
$-0.01B |
$0.02B |
-50.53% |
| 2016-06-30 |
$-0.01B |
$0.02B |
-54.74% |
| 2016-03-31 |
$-0.01B |
$0.03B |
-55.45% |
| 2015-12-31 |
$-0.01B |
$0.03B |
-53.33% |
| 2015-09-30 |
$-0.01B |
$0.02B |
-45.61% |
| 2015-06-30 |
$-0.01B |
$0.03B |
-34.65% |
| 2015-03-31 |
$-0.01B |
$0.03B |
-23.02% |
| 2014-12-31 |
$-0.02B |
$0.03B |
-50.67% |
| 2014-09-30 |
$-0.02B |
$0.04B |
-58.82% |
| 2014-06-30 |
$-0.02B |
$0.04B |
-68.97% |
| 2014-03-31 |
$-0.02B |
$0.04B |
-104.55% |
| 2013-12-31 |
$-0.01B |
$0.02B |
-66.67% |
| 2013-09-30 |
$-0.01B |
$0.02B |
-50.91% |
| 2013-06-30 |
$-0.01B |
$0.01B |
-68.09% |
| 2013-03-31 |
$-0.01B |
$0.01B |
-52.17% |
| 2012-12-31 |
$-0.01B |
$0.02B |
-53.33% |
| 2012-09-30 |
$-0.01B |
$0.01B |
-54.55% |
| 2012-06-30 |
$-0.00B |
$0.01B |
-29.09% |
| 2012-03-31 |
$-0.01B |
$0.01B |
-53.73% |
| 2011-12-31 |
$-0.01B |
$0.01B |
-53.66% |
| 2011-09-30 |
$-0.01B |
$0.02B |
-66.67% |
| 2011-06-30 |
$-0.01B |
$0.02B |
-62.65% |
| 2011-03-31 |
$-0.01B |
$0.03B |
-54.32% |
| 2010-12-31 |
$-0.02B |
$0.02B |
-93.75% |
| 2010-09-30 |
$-0.01B |
$0.02B |
-68.97% |
| 2010-06-30 |
$-0.01B |
$0.02B |
-93.62% |
| 2010-03-31 |
$-0.01B |
$0.01B |
-112.50% |
| 2009-12-31 |
$-0.00B |
$0.01B |
-32.00% |
| Sector |
Industry |
Market Cap |
Revenue |
|
|
$0.000B |
$0.000B |
|
Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals Inc., is based in FARMINGTON HILLS, Mich.
|
